We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, June 2, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Fitness-enhanced CEA-targeting CAR T cells for...
The annual biotech strategic meeting at the NYSE convenes a highly curated group of biotech executives, investors and drug development leaders to explore the most pressing strategic questions shaping the future of immuno-oncology. The program will feature discussions on late-stage and...
06-26-2026 | 08:00 - 15:35 ET New York NY
We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, June 1, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Live biotherapeutic CBM588 improves the...
We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 31, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Final safety, efficacy and biomarker...
A Message from the President The pace of discovery in cancer immunotherapy continues to accelerate, creating both extraordinary opportunity and an urgent need for collaboration. For more than 40 years, the Society for Immunotherapy of Cancer (SITC) Annual Meeting has helped drive these...
We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 30, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Tumor-specific MHC-II as a prospective...
We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 29, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Azer-cel, an allogeneic CAR T cell, for relapsed...
The Society for Immunotherapy of Cancer (SITC) joined more than 60 cancer patient and provider organizations in signing onto a coalition letter led by the American Cancer Society Cancer Action Network (ACS CAN) directed to Secretary Kennedy in support of protecting the scientific integrity and...
Edited by Tanja D. de Gruijl, PhD and Howard Kaufman, MD, FACS While local immunotherapy has the potential to deliver high doses of immune potentiating agents with limited systemic toxicity, clinical development and implementation have been hindered by numerous challenges. This special...
The Society for Immunotherapy of Cancer (SITC) joined more than 50 organizations through One Voice Against Cancer (OVAC) in signing a coalition letter to Congress raising concerns about delays and disruptions in federal cancer research funding. View the letter in its entirety at this LINK . ...